Hepatic steatosis in women with polycystic ovary syndrome

BMC Endocrine Disorders

Table 7 Risk factors of NAFLD in different age groups of PCOS

	18 ~ 25 years, N(%)	26 ~ 30 years, N(%)	Over 30 years, N(%)	P
Central obesity	22 (50.0%)	44 (44.9%)	43 (70.5%)**	0.006
Increased blood pressure	6 (20.7%)*	9 (32.1%)	12 (48.0%)*	0.103
Hypertriglyceridemia	3 (6.7%)*	20 (18.7%)	17 (27.0%)*	0.028
Hyperlipidemia	11 (24.4%)**	45 (42.1%)	33 (52.4%)	0.014
Abnormal blood glucose	10 (22.2%)	24 (22.4%)	20 (32.3%)	0.319
HOMA-IR ≥ 3.54	15 (34.9%)	30 (28.6%)	16 (27.1%)	0.669
Metabolic syndrome	8 (17.0%)	14 (13.1%)	14 (22.2%)	0.301
Abnormal liver enzymes	8 (17.0%)	12 (11.2%)	8 (12.7%)	0.612
ALT ≥ 18.2	21 (44.7%)	48 (44.9%)	27 (42.9%)	0.966
FAI > 8	16 (40.0%)	39 (41.9%)	23 (42.6%)	0.967
Hirsutism	19 (41.3%)	35 (33.7%)	16 (25.8%)	0.234
Acne	23 (50.0%)	54 (51.9%)	22 (34.9%)*	0.088
PCOM	40 (90.9%)	84 (90.3%)	50 (90.9%)	0.990

The ‘N (%)’ in each cell represented ‘the number of patients with this risk factor in this age group (the percentage of patients with this risk factor in this age group)’. Patients were excluded if the factor to be analyzed was missing
Central obesity was defined as waist circumference ≥ 80 cm; overweight as BMI ≥ 24 kg/m². Abnormal blood glucose was defined as pre-diabetes (in the definition of MAFLD, i.e. the ADA definition) or diabetes, or related drug treatment. Hyperlipidemia was defined as TG ≥ 1.7 mmol/L or TC ≥ 5.70 mmol/L or LDL-c ≥ 3.37 mmol/L or HDL-c < 0.93 mmol/L. Other definitions were described previously
The specific p values between any 2 groups were listed in Supplementary Table 5
** significant difference with other 2 groups (p < 0.05)
* significant difference with the other group marked with ‘*’ (p < 0.05)

ISSN: 1472-6823